<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04108104</url>
  </required_header>
  <id_info>
    <org_study_id>KT-100-001</org_study_id>
    <nct_id>NCT04108104</nct_id>
  </id_info>
  <brief_title>Clinical Outcome of a Patented Pharmaceutical Composition (KT-110) to Treat Alcohol Use Disorder While Avoiding Major Side Effects</brief_title>
  <acronym>COCKTAIL</acronym>
  <official_title>Double-blind, Randomised, Parallel-group, Three-arm, Dose Range, Placebo-controlled, Proof-of-concept Study to Evaluate the Efficacy, Tolerability and Safety of a Combination of Cypropheptadine and Prazosin on Alcohol Consumption in Patients With Severe Alcohol Use Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kinnov Therapeutics</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ECSOR</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kinnov Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Double-blind randomised, parallel-group, three-arm, multicentre, placebo-controlled study The
      primary objective is to demonstrate the superiority of the combination of Periactine®
      (cyproheptadine 8 mg/day or 12 mg/day) and Alpress® (prazosin 5 mg/day or 10 mg/day) over
      placebo on the reduction of the total alcohol consumption (TAC), in alcohol-dependent
      patients.

      180 patients will be randomised into the two treatment groups (N=60 in the low-dose group and
      N=60 in the high-dose group) and the placebo group (N=60).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 30, 2019</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the mean quantity of alcohol consumed per day in the three groups</measure>
    <time_frame>weeks 9 to 12</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Alcohol Use Disorder</condition>
  <arm_group>
    <arm_group_label>Low-dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Periactine® (Cyproheptadine 8 mg/day; two times 4 mg: morning and evening) and Alpress® (5 mg once a day slow-release: evening administration).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Periactine® (Cyproheptadine 12 mg/day; three times 4 mg: morning, noon and evening) and Alpress® (10 mg [2 tablets of 5 mg] once a day slow-release: evening administration)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo of Periactine® (three times per day: morning, noon and evening) and placebo of Alpress® (once a day: evening)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyproheptadine</intervention_name>
    <description>3-month treatment</description>
    <arm_group_label>High-dose group</arm_group_label>
    <arm_group_label>Low-dose group</arm_group_label>
    <arm_group_label>Placebo group</arm_group_label>
    <other_name>Periactine®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alpress LP</intervention_name>
    <description>3-month treatment</description>
    <arm_group_label>High-dose group</arm_group_label>
    <arm_group_label>Low-dose group</arm_group_label>
    <arm_group_label>Placebo group</arm_group_label>
    <other_name>Prazosin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Severe alcohol use disorder

          -  High-risk alcohol consumption

        Exclusion Criteria:

          -  Patient with orthostatic hypotension

          -  Patient with hypotension

          -  History of uncontrolled hypertension

          -  Patient at risk for urinary retention associated with urethroprostatic disorders

          -  Patient with a clinically-active malignancy

          -  Patient with a confirmed cirrhosis

          -  History of bronchial asthma

          -  History of uncontrolled hyperthyroidism

          -  History of cardiovascular disease not under control

          -  Severe psychiatric disorder

          -  History of alcohol withdrawal syndrome
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alain Puech</last_name>
    <role>Study Director</role>
    <affiliation>Kinnov Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lucas Biela</last_name>
    <phone>+33(0)674344966</phone>
    <email>lb@kinnov-therapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Hospitalier d'Abbeville</name>
      <address>
        <city>Abbeville</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maroussia Wilquin-Leblanc, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>SUAL Le Vinatier</name>
      <address>
        <city>Bron</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin Rolland, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Georges Brousse, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Albert Chenevier</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Baptiste Trabut</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benoît Trojak, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Camille Claudel</name>
      <address>
        <city>La Couronne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Batel, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH La Rochelle</name>
      <address>
        <city>La Rochelle</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Bendimerad, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble - La Tronche</name>
      <address>
        <city>La Tronche</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maurice Dematteis, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Psychotherapique de Nancy</name>
      <address>
        <city>Laxou</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>François Paille, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Emile-Roux</name>
      <address>
        <city>Le Puy-en-Velay</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier Esquirol</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Nubukpo, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Lyon Hôpital de la Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François Bailly, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Provences-Alpes Côte d'Azur Hôpital Publique</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Simon, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes - site Hôtel-Dieu</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Nice</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Universitaire Carémeau</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHR Orléans</name>
      <address>
        <city>Orléans</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Damien Labarriere, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>GHR Sainte-Anne</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier Laqueille, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Fernand-Widal</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Questel, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes - Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse - Hôpital Purpan</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicolas Franchitto, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Annecy Genevois</name>
      <address>
        <city>Épagny</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume Ouziel, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 25, 2019</study_first_submitted>
  <study_first_submitted_qc>September 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2019</study_first_posted>
  <last_update_submitted>March 16, 2020</last_update_submitted>
  <last_update_submitted_qc>March 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Alcohol Drinking</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyproheptadine</mesh_term>
    <mesh_term>Prazosin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

